

WFS1 A179T — Wolframin

Alanine → Threonine at position 179. N-terminal cytoplasmic (intrinsically disordered). ClinVar Uncertain significance/Uncertain risk allele, AlphaMissense 0.934, DynaMut2 $\Delta\Delta G$ -2.09 kcal/mol (destabilising).

IDENTITY

Variant	A179T (p.Alanine179Threonine)
DNA change	c.535G>A
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV000229647
Amino acid change	Alanine (A) → Threonine (T)

STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 179	88.56 HIGH CONFIDENCE
Domain	N-terminal cytoplasmic (intrinsically disordered)
Position context	N-terminal cytoplasmic (intrinsically disordered)
IDR flag	No — pLDDT well above 50 threshold

Position 179 sits in N-terminal cytoplasmic (intrinsically disordered). The wild-type residue is small/hydrophobic (alanine — methyl sidechain); the mutant is small polar (threonine — hydroxyl). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

0.934am_class: **likely pathogenic** — threshold > 0.564DYNAMUT2 $\Delta\Delta G$ **-2.09** kcal/molDestabilising · Job
178092143728

PLDDT (ALPHAFOLD)

88.56

high confidence

CLINICAL EVIDENCE

ClinVar classification	UNCERTAIN SIGNIFICANCE/UNCERTAIN RISK ALLELE
Review status	criteria provided, multiple submitters, no conflicts
Last evaluated	2026/02/23 00:00
Inheritance	Autosomal dominant pattern indicated by associated DFNA6/14/38 (WFS1 hearing loss 6).
WFS1 variant landscape	A179T is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar) <ul style="list-style-type: none"> • Cataract 41 • Autosomal dominant nonsyndromic hearing loss 6 • Type 2 diabetes mellitus • Wolfram syndrome 1 • Wolfram-like syndrome • Inborn genetic diseases

RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$ + binding site affected → CATEGORY 3 – docking experiments $\Delta\Delta G 2-4$ → CATEGORY 2 – pharmacological chaperones $\Delta\Delta G > 4$ → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

Category 2 — Moderately Destabilizing

$|\Delta\Delta G|=2.09$ in the 2–4 range. Pharmacological chaperone candidate.